Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review

References

• Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417–1427.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Thyssen JP, Burisch J, et al. Incidence and risk of inflammatory bowel disease in patients with psoriasis-a nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316–323.
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Tekin HG, Burisch J, et al. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and meta-analysis. J Crohn’s Colit. 2020;14(3):351–360.
   PubMed Web of Science ®Google Scholar
• Vlachos C, Gaitanis G, Katsanos KH, et al. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis. 2016;6:73–92.
   PubMedGoogle Scholar
• Cottone M, Sapienza C, Macaluso FS, et al. Psoriasis and inflammatory bowel disease. Dig Dis. 2019;37(6):451–457.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Imaeda H, Takahashi K, et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol. 2013;28(4):613–619.
   PubMed Web of Science ®Google Scholar
• Eppinga H, Sperna Weiland CJ, Thio HB, et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in Hidradenitis Suppurativa. ECCOJC. 2016;10(9):1067–1075.
   Web of Science ®Google Scholar
• Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383–394.
   PubMed Web of Science ®Google Scholar
• Fieldhouse KA, Ukaibe S, Crowley EL, et al. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. DIC. 2020;9:1–9.
   Google Scholar
• Stelara (ustekinumab) for intravenous and subcutaneous use. Horsham (PA): Janssen Biotech; October 2017. (package insert). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf.
   Google Scholar
• Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Therapeut. 2018;48(1):65–77.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: Three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's Disease. J Crohn’s Colit. 2020;14(1):23–32.
   PubMed Web of Science ®Google Scholar
• Li K, Friedman JR, Chan D, et al. Effects of ustekinumab on histologic disease activity in patients with Crohn’s disease. Gastroenterology. 2019;157(4):1019–1031.e7.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease. Gastroenterology. 2018;154(6):1660–1671.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn’s disease: an integrated analysis of phase II/III clinical development programs. Drug Saf. 2019;42(6):809–809.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease. Gastroenterology. 2018;155(4):1045–1058.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• Weaver KN, Gregory M, Syal G, et al. Ustekinumab is effective for the treatment of Crohn's disease of the pouch in a multicenter cohort. Inflammat Bowel Dis. 2019;25(4):767–774.
   PubMed Web of Science ®Google Scholar
• Chateau T, Peyrin-Biroulet L. Two cases of inflammatory bowel disease patients treated with ustekinumab 90 mg every 3 weeks. Inflammat Bowel Dis. 2020;26(2):e7.
   PubMed Web of Science ®Google Scholar
• Kolios AGA, Biedermann L, Weber A, et al. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. British J Dermatol. 2018;178(2):551–555.
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy. Rheumatol Int. 2018;38(7):1297–1299.
   PubMed Web of Science ®Google Scholar
• Suh HY, Ahn JY, Youn Park M, et al. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy. J Dermatol. 2018;45(3):332–333.
   PubMed Web of Science ®Google Scholar
• García García MJ, Rivero Tirado M, Peiró Callizo ME. Paradoxical arthritis in inflammatory bowel diasease patients on ustekinumab treatment. Inflamm Bowel Dis. 2019;25(7):e89.
   PubMed Web of Science ®Google Scholar
• Onsun N, Yalcin B, Sallahoglu K, et al. Worsening of psoriatic arthritis after ustekinumab treatment. Am J Ther. 2018;25(3):e381–e382.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease. Biolog Target Ther. 2018;12:69–73.
   Web of Science ®Google Scholar
• Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. 2018;391(10136):2213–2224.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. 2020;395(10230):1115–1125.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. 2020;395(10230):1126–1136.
   PubMed Web of Science ®Google Scholar
• Berman HS, Villa NM, Shi VY, et al. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J Dermatol Treat. 2019;25:1–3.
   Web of Science ®Google Scholar
• Grossberg LB. A case report of successful treatment of Crohn's disease and psoriasis with guselkumab. Inflammat Bowel Dis. 2019;25(7):e84.
   PubMed Web of Science ®Google Scholar
• Shaw CA, Kole LCS, Elewski BE. Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy. J Eur Acad Dermatol Venereol. 2019;33(11):e431–e432.
   PubMed Web of Science ®Google Scholar
• Vulliemoz M, Brand S, Juillerat P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology, et al. TNF-alpha blockers in inflammatory bowel diseases: practical recommendations and a user’s guide: an update. Digestion. 2020;101(Suppl. 1):16–11.
   PubMed Web of Science ®Google Scholar
• Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Prob Dermatol. 2018;53:49–63.
   PubMedGoogle Scholar
• Zheng J, Gao Y, Ding Y. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis. Dermatol Ther. 2019;32(6):e13132.
   PubMed Web of Science ®Google Scholar
• Koumaki D, Koumaki V, Katoulis A, et al. Adalimumab-induced scalp psoriasis with severe alopecia as a paradoxical effect in a patient with Crohn’s disease successfully treated with ustekinumab. Dermatol Ther. 2020;33(4).
   Web of Science ®Google Scholar
• Zangrilli A, Bavetta M, Mazzilli S, et al. Paradoxical case effects of psoriasis following adalimumab therapy: a case series. Dermatol Ther. 2018;31(6):e12729.
   PubMed Web of Science ®Google Scholar
• Özkur E, Altunay İK, Leblebici C, et al. Adalimumab-induced scalp psoriasis with severe alopecia. Dermatol Ther. 2019;32(5):e13033.
   PubMed Web of Science ®Google Scholar
• Shimokata M, Namiki T, Tokoro S, et al. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab. J Dermatol. 2018;45(12):e331–e333.
   PubMed Web of Science ®Google Scholar
• Buckley LH, Xiao R, Perman MJ, et al. Psoriasis associated with tumor necrosis factor-alpha inhibitors in children with inflammatory diseases. Arthritis Care Res. 2019. doi:10.1002/acr.24100
   Web of Science ®Google Scholar
• Bonomo L, de Moll EH, Li L, et al. Tumor necrosis factor inhibitor-induced psoriasis in a pediatric Crohn's disease patient successfully treated with ustekinumab. J Drugs Dermatol. 2020;19(3):328–331.
   PubMed Web of Science ®Google Scholar
• Courbette O, Aupiais C, Viala J, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease. J Pediat Gastroenterol Nutrit. 2019;69(2):189–193.
   PubMed Web of Science ®Google Scholar
• Weizman AV, Sharma R, Afzal NM, et al. Stricturing and fistulizing Crohn's disease is associated with anti-tumor necrosis factor-induced psoriasis in patients with inflammatory bowel disease. Digest Dis Sci. 2018;63(9):2430–2438.
   PubMed Web of Science ®Google Scholar
• Elewaut D, Braun J, Anderson JK, et al. Low incidence of inflammatory bowel disease adverse events in adalimumab clinical trials across nine different diseases. Arthritis Care Res. 2020. doi:10.1002/acr.24175
   Web of Science ®Google Scholar
• Korzenik J, Larsen MD, Nielsen J, et al. Increased risk of developing Crohn's disease or ulcerative colitis in 17,018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Therapeut. 2019;50(3):289–294.
   PubMed Web of Science ®Google Scholar
• Forouzandeh M, Vazquez T, Nouri K, et al. The paradoxical induction of Crohn’s disease following treatment of psoriatic arthritis with etanercept. J Drugs Dermatol. 2019;18(8):832–834.
   PubMed Web of Science ®Google Scholar
• Valdivielso Cortázar E, Diz-Lois Palomares MT, Alonso Aguirre P. Crohn's disease in patients treated with etanercept. Rev Esp Enferm Dig. 2020;112(1):80–81.
   PubMed Web of Science ®Google Scholar
• Tolu S, Rezvani A, Hindioglu N, et al. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature. Rheumatol Int. 2018;38(11):2157–2162.
   PubMed Web of Science ®Google Scholar
• Burisch J, Eigner W, Schreiber S, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLOS One. 2020;15(5):e0233781.
   PubMed Web of Science ®Google Scholar
• Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019;19(1):45–54.
   PubMed Web of Science ®Google Scholar
• Wang J, Bhatia A, Krugliak Cleveland N, et al. Rapid onset of inflammatory bowel disease after receiving Secukinumab infusion. ACG Case Rep J. 2018;5:e56.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheumat Dis. 2019;78(4):473–479.
   PubMed Web of Science ®Google Scholar
• Wright S, Alloo A, Strunk A, et al. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors. J Am Acad Dermatol. 2020;83(2):382–387.
   PubMed Web of Science ®Google Scholar
• Emond B, Ellis LA, Chakravarty SD, et al. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Curr Med Res Opin. 2019;35(10):1751–1759.
   PubMed Web of Science ®Google Scholar
• Nehring P, Przybyłkowski A. Is psoriasis treatment a risk factor for inflammatory bowel disease? Pharm Med. 2020;34(4):257–262.
   PubMed Web of Science ®Google Scholar
• Yamada A, Wang J, Komaki Y, et al. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Therapeut. 2019;50(4):373–385.
   PubMed Web of Science ®Google Scholar
• Fauny M, Moulin D, D'Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–1138.
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatol Treat. 2018;29(1):13–18.
   PubMed Web of Science ®Google Scholar
• McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79(8):893–900.
   PubMed Web of Science ®Google Scholar
• Wang Y, Mao Y, Zhang J, et al. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med. 2018;22(2):1014–1025.
   PubMed Web of Science ®Google Scholar
• Jia Y, Anwaar S, Li L, et al. A new target for the treatment of inflammatory bowel disease: Interleukin-37. Int Immunopharmacol. 2020;83.
   Web of Science ®Google Scholar